RxDoctor Payments Data

Svetlana Brothers, NP

Nurse Practitioner · Albuquerque, NMNPI 1437485893

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 35.8% of the total. 2025 is the largest year on record at $1,318, 3.4 times the $388 reported in 2021. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,560in general payments, 2019–2025

Across 106 payments — averaging $33.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$573
  • Johnson & Johnson$366
  • Gilead$297
  • Takeda Pharmaceuticals U.S.A., Inc.$289
  • E.r. Squibb & Sons, L.L.C.$206
  • plus $556 from 9 others

What the payments were for

  • Food & beverage$3,45397%
  • Education$1073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,560 in reported general payments places this provider in the 95th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$34,798
Medicare patients
321
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$30,956
LinzessLinaclotide19$11,126
Omeprazole170$2,770
Famotidine91$2,312
Esomeprazole Magnesium15$919
Lactulose11$830
Pantoprazole Sodium56$638
Dicyclomine Hcl14$370
Amitriptyline Hcl17$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,274$42,08238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →